TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

Benzinga Logo Benzinga By Prnewswire
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

Dynavax reported strong Q3 2025 financial results, with HEPLISAV-B vaccine revenue increasing 13% to $90 million. The company entered an exclusive license agreement with Vaxart for an oral COVID-19 vaccine and authorized a new $100 million share repurchase program.

Insights
TSM   neutral

Leads in 2 nm process maturity, but Intel acknowledges technological parity challenges


DVAX   positive

Strong quarterly revenue growth, expanding vaccine pipeline, new licensing deal, and confident share repurchase program indicate positive business performance